Albertsons Companies, Inc. (ACI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session highlight several positive factors: consistent growth in digital and e-commerce, strong productivity initiatives, and strategic investments in AI and technology. Despite challenges like higher fuel costs and opioid settlements, the company plans to fund share repurchases through working capital improvements. The pharmacy business is expected to grow, and loyalty programs are enhancing customer engagement. While there are some concerns, such as unclear store expansion details, the overall sentiment is positive, indicating a likely stock price increase of 2% to 8%.
Key Financial Performance
Identical Sales (Q4) Increased by 0.7%, net of approximately 145 basis points of pharmacy-related headwinds. The headwinds were due to the Inflation Reduction Act (IRA) and broader industry affordability dynamics.
Adjusted EBITDA (Q4) $903 million, including approximately $68 million related to the 53rd week. Better-than-expected performance due to productivity and cost-containment measures.
Gross Margin (Q4) 27.2%, a decline of 25 basis points year-over-year, excluding fuel and LIFO. The decrease was driven by the mix shift impact of outsized growth in digital sales, offset by productivity benefits.
Selling and Administrative Expense (Q4) Improved by 2 basis points year-over-year, excluding the impact of fuel and the opioid settlement framework. Reflects accelerated productivity and cost-containment discipline.
Interest Expense (Q4) Increased by $40 million to $141 million compared to $101 million last year. The increase was due to higher borrowings and the extra week in the fourth quarter of 2025.
Adjusted EPS (Q4) $0.48 per diluted share. Productivity measures contributed to better-than-expected results.
Identical Sales (Full Year) Increased by 2%. Reflects resilience in the operating model and productivity improvements.
Adjusted EBITDA (Full Year) $3.9 billion. Reflects the ability to reinvest in the business and return capital to shareholders.
Capital Expenditures (Full Year) $1.84 billion. Investments were made in store modernization, AI, digital and technology capabilities, and supply chain elevation.
Shareholder Returns (Full Year) $1.8 billion returned to shareholders, including $322 million in dividends and nearly $1.5 billion in share repurchases.
Net Debt to Adjusted EBITDA Ratio (End of Year) 2.24x. Demonstrates financial strength and capacity to fund growth and shareholder returns.
Digital Penetration (Q4) Surpassed 10%, contributing to a 16% digital growth. First-party business contributed nearly 90% of this growth.
Membership Growth (Q4) Increased by 12% to more than 51 million members. Reflects higher spending and frequent transactions among engaged households.
Pharmacy Profitability (Q4) Improved despite top-line pressure from the Inflation Reduction Act. Performance was supported by operational productivity and higher-margin services.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Digital and e-commerce business: Digital penetration surpassed 10% in Q4, contributing to 16% digital growth. AI-enabled shopping assistance is enhancing personalization and increasing basket size.
Food Now Expansion: Expanding into meal solutions, with deli and prepared foods driving more than 1/3 of total trips.
Winning Footprint: Stores are within 15 minutes of 120 million people, providing a structural advantage in trip frequency, pharmacy access, and same-day fulfillment.
Loyalty Ecosystem: Membership grew 12% to over 51 million members, driving higher spending and deeper engagement.
AI and Technology Integration: AI-driven tools are improving customer personalization, labor optimization, supply chain efficiency, and merchandising intelligence.
Productivity Program: Launched a $2 billion 3-year productivity program to enhance operational efficiency and reinvest in growth.
Balanced Value Proposition: Focused on affordability, transparency, and data-driven personalization to meet diverse customer needs.
Pharmacy Strategy: Improved profitability through central fill, enhanced procurement, and scaling higher-margin services despite regulatory headwinds.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Pharmacy Headwinds: Greater-than-expected pharmacy headwinds, including the Inflation Reduction Act (IRA) pricing and mix pressure, as well as a shift toward a higher generic-to-brand mix, created significant sales headwinds. These factors impacted identical sales by approximately 145 basis points in Q4.
Economic Pressure on Low-Income Cohorts: Units and identical sales in grocery remained pressured in the lowest income cohorts, reflecting economic challenges and reduced consumer spending power.
Deflationary Pressures: Deflation, particularly in categories like eggs, created meaningful sales headwinds, which are expected to persist into the first quarter of 2026.
Regulatory and Reimbursement Challenges in Pharmacy: The Inflation Reduction Act and broader regulatory dynamics are creating ongoing top-line headwinds in the pharmacy segment, impacting sales and requiring disciplined management of reimbursement.
Competitive Intensity in Food Retail: The food retail industry remains highly competitive, requiring Albertsons to continuously differentiate its offerings and maintain a balanced value proposition to retain customers.
Supply Chain and Operational Productivity: While productivity improvements are being made, the company faces ongoing challenges in scaling AI-powered tools and maintaining operational efficiency across labor, supply chain, and merchandising.
Opioid Litigation Settlement: The company announced a $774 million settlement framework for opioid-related litigation, payable over nine years, which represents a financial burden and potential reputational risk.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Dividend Increase: Albertsons announced a 13% increase in its quarterly dividend to $0.68 per share, reflecting confidence in its financial position and commitment to shareholder returns.
Share Repurchase Authorization: The company refreshed its share repurchase authorization to $2 billion, expected to be completed over the next three years.
Capital Expenditures for Fiscal 2026: Albertsons plans to invest $2 billion to $2.2 billion in fiscal 2026, focusing on new stores, remodels, AI-powered technologies, and digital capabilities.
Identical Sales Growth: For fiscal 2026, identical sales are expected to grow between 0% to 1%, or 1.5% to 2.5% excluding a 150 basis point headwind from the Inflation Reduction Act.
Adjusted EBITDA: The company projects adjusted EBITDA for fiscal 2026 to be in the range of $3.85 billion to $3.925 billion, representing growth of approximately 2.5% at the top end of the range, excluding the 53rd week impact in 2025.
Adjusted EPS: Adjusted EPS is expected to range between $2.22 and $2.32, including approximately $600 million of share repurchases during fiscal 2026.
Pharmacy Business Outlook: Albertsons expects continued improvement in pharmacy scripts, supported by immunizations and value-added clinical services, despite top-line headwinds from the Inflation Reduction Act.
Digital and E-commerce Growth: The company anticipates digital and e-commerce to remain a strong growth engine, with continued scaling of its first-party business and AI-enabled shopping assistance driving higher conversion and larger basket sizes.
Productivity Program: Albertsons is launching a $2 billion three-year productivity program to drive efficiencies across labor, store operations, supply chain, and merchandising, supported by AI and technology investments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends Paid in Fiscal 2025: $322 million in dividends were paid to shareholders.
Increase in Quarterly Dividend: Quarterly dividend increased by 13% to $0.68 per share.
Share Repurchase in Fiscal 2025: Nearly $1.5 billion in share repurchases, including the completion of a $750 million accelerated share repurchase program.
New Share Repurchase Authorization: Existing share repurchase authorization refreshed to $2 billion, expected to be completed over approximately the next 3 years.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more detail on productivity efforts and the split between COGS and SG&A?
A:The company has reset its productivity target to $2 billion over the next 3 years, distributed ratably. Key areas include store operations, shrinkage, Rx, sourcing (GNFR and admin areas), and supply chain. Most savings will come from SG&A. AI investments and 'buying better together' initiatives are yielding strong results.
Q:Can you provide more detail on the grocery side, including volumes and inflation outlook?
A:Reported IDs of 0%-1% include a 150 basis point headwind from the IRA, with underlying business running closer to 1.5%-2%. The company is focusing on quality top-line growth through loyalty, digital personalization, fresh penetration, and closing pricing gaps funded by productivity. Industry units are expected to remain pressured in the first half of the year, with sequential improvement and likely positive growth in the back half.
Q:Have you seen much of a step change in competitors' value propositions, and do you anticipate deeper investments in specific markets?
A:The company has closed the pricing gap versus MULO in Q4 and is taking a surgical approach to pricing, focusing on key value items, private label, loyalty, and personalization. Investments are funded through structural productivity and margin improvement, not short-term trade-offs.
Q:What are the implications of higher fuel prices due to the Middle East conflict?
A:The company expects food inflation to run around 2% but is not passing through the full rate to bolster price position. Lower-income cohorts are under increasing pressure, and the company is focusing on value perception through surgical actions. Fuel margins are expected to remain near flat, assuming the conflict ends in a reasonable period.
Q:Can you provide more color on gross margin expectations for the upcoming year?
A:Gross margin is expected to be flat to slightly better in 2026, benefiting from the IRA and productivity initiatives. Digital business growth is less impactful on margins due to improved profitability. Higher fuel costs are included in the outlook, with potential incremental pressure if the Middle East conflict persists.
Q:What are the offsets to increased CapEx and opioid settlement headwinds in delivering share repurchase guidance?
A:The company expects improvements in working capital to fund about half of the share repurchase. CapEx investments in store fleet and productivity initiatives are expected to yield returns in the back half of the year, supporting cash flow and leverage.
Q:If comps improve, will the company reinvest or let it flow through to earnings?
A:The company will evaluate based on momentum. If units inflect faster, they will invest behind customer growth to catalyze long-term improvements in their algorithm.
Q:What are the KPIs and growth expectations for e-commerce?
A:Digital penetration has surpassed 10%, with sales growing 16% in Q4 and over 40% on a 2-year stack. 90% of digital sales come from first-party, with strong execution in delivery times and customer satisfaction. The company sees significant upside in digital growth.
Q:What are the assumptions for fuel profits and own brand performance in FY '26?
A:Fuel profits are expected to remain near flat, assuming the Middle East conflict ends reasonably soon. Own brand penetration is currently flat but is a top priority for 2026, with investments in team restructuring, cost negotiation, and quality improvements.
Q:Is it reasonable to expect positive food volumes by the end of 2026?
A:The company expects an inflection in food volumes throughout the year, with positive growth anticipated by year-end, assuming industry units improve.
Q:What is the progress and opportunity in sourcing better together?
A:The company is in the fourth or fifth inning of its 'buying better together' initiative. New leadership and team restructuring have led to increased national sales events, lower own brand costs, and improved vendor partnerships to amplify value while protecting margins.
Q:Is the new higher CapEx range a baseline going forward, and what are the plans for new stores and remodels?
A:The company plans to increase new store openings by 50% and amplify remodels materially in 2026. The CapEx range may remain if returns from these investments meet expectations, with updates provided later in the year.
Q:What are the key priorities and surprises in retail media?
A:The company is accelerating growth in its media collective, improving return on advertising spend for vendors, and experimenting with personalized ads, which have shown strong customer and vendor response. Retail media is a key driver of productivity and unit growth.
Q:What is the expected cadence of earnings growth in 2026?
A:Earnings growth will be most pressured in Q1 due to comp sales below ID sales range. Adjusted EBITDA growth is expected in every subsequent quarter, improving sequentially as productivity initiatives take effect.
Q:When will store-level investments and technology benefits materialize?
A:Early remodels will show benefits in the back half of 2026, with more significant contributions in 2027. Technology investments, such as the Gateway initiative, are expected to yield benefits throughout 2026.
Q:How does the company address market share erosion despite loyalty growth?
A:The company is leveraging proximity, fresh offerings, and personalized value to stop second trips to competitors. Initiatives include improving in-stock levels, fair pricing, and fresh penetration to enhance customer preference.
Q:How does the company balance shelf price and promotional pricing to improve value perception?
A:The company takes a surgical approach to pricing, varying strategies by market. Investments in frontline and promotional pricing are tailored to customer needs, with strong results in key divisions.
Q:What is the impact of GLP-1 drugs on store traffic and sales?
A:GLP-1 pressure is expected to continue due to payer restrictions. The company believes GLP-1 users will remain store customers, and pharmacy script count is still growing, contributing to traffic and larger baskets.
Q:What is the impact of increased cross-shopping and digital growth on store traffic?
A:Store traffic remains steady, with the company focusing on stopping second trips through sharper value, loyalty engagement, and fresh differentiation. Digital growth complements in-store traffic by enhancing customer experience.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific number of new stores planned for 2026, providing only a general statement about a 50% increase from the previous year. Additionally, they did not provide detailed metrics or specific growth targets for retail media, instead focusing on qualitative improvements and experiments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI technology
Act
IRA pharmacy
Inflation Reduction
base
bet
conversion
cycle
deflation
dividend share
dynamic
egg
experience scale
fulfillment
generation
grocer neighborhood
headwind ID
headwind IRA
life
market store
mission
model ability
momentum
note
optimization
personalization
pharmacy IRA
pharmacy headwind
point headwind
rate sale
redemption
return
service
settlement framework
share food
speed
step
store network
strength store
technology capability
trip
week share
ACI Transcript
Albertsons Companies, Inc. (ACI) Q4 2025 Earnings Call Transcript
Positive4-14
The earnings call summary and Q&A session highlight several positive factors: consistent growth in digital and e-commerce, strong productivity initiatives, and strategic investments in AI and technology. Despite challenges like higher fuel costs and opioid settlements, the company plans to fund share repurchases through working capital improvements. The pharmacy business is expected to grow, and loyalty programs are enhancing customer engagement. While there are some concerns, such as unclear store expansion details, the overall sentiment is positive, indicating a likely stock price increase of 2% to 8%.
Cameco Corporation (CCO:CA) Presents at Goldman Sachs Energy, CleanTech & Utilities Conference Transcript
Neutral1-7
Albertsons Companies, Inc. (ACI) Q3 2026 Earnings Call Transcript
Positive1-7
The earnings call summary and Q&A session reveal strong growth in pharmacy and digital sales, optimistic guidance, and effective cost savings initiatives. Despite concerns about inflation and promotional environment, the company's strategic investments in technology and customer engagement are promising. Share repurchase plans and improved EPS guidance also contribute positively. Overall, these factors suggest a positive stock price movement over the next two weeks.
Albertsons Companies, Inc. (ACI) Q2 2025 Earnings Call Transcript
Unknown10-14
The earnings call presents a mixed outlook. While there are positive developments in digital platforms, pharmacy growth, and productivity initiatives, the unchanged EBITDA and EPS guidance, coupled with no significant margin changes, tempers enthusiasm. The Q&A reveals cautious optimism with a focus on strategic investments and AI integration, but lacks detailed timelines or strong financial impacts. Overall, the sentiment is balanced, leading to a neutral prediction.
ACI Slides
ACI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
